153 related articles for article (PubMed ID: 15297407)
1. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
[TBL] [Abstract][Full Text] [Related]
4. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
13. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Zhu AX; Ready N; Clark JW; Safran H; Amato A; Salem N; Pace S; He X; Zvereva N; Lynch TJ; Ryan DP; Supko JG
Clin Cancer Res; 2009 Jan; 15(1):374-81. PubMed ID: 19118068
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J; Simon GR; Garrett CR; Springett G; De Conti R; Chiappori AA; Munster PN; Burton MK; Stromatt S; Allievi C; Angiuli P; Eisenfeld A; Sullivan DM; Daud AI
Clin Cancer Res; 2007 Oct; 13(19):5855-61. PubMed ID: 17908979
[TBL] [Abstract][Full Text] [Related]
18. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]